Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …

Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …

Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

Background: The role of remdesivir in the treatment of patients in hospital with COVID-19
remains ill defined in a global context. The World Health Organization Solidarity randomized …

Purpose This review was aimed to synthesise the best available evidence on the
effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19 …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

Abstract Background World Health Organization expert groups recommended mortality trials
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …

Background Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We
systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19 …

Background: Remdesivir is approved for the treatment of adults hospitalized with COVID-19.
Purpose: To update a living review of remdesivir for adults with COVID-19. Data Sources …

Background The benefits of remdesivir in the treatment of hospitalized patients with COVID-
19 remain debated with the National Institutes of Health and the World Health Organization …